載入中
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
前收盤價
US$5.97
+US$0.31 · +5.48%
盤中時間採用ET。市場資料可能有所延遲。
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
日內區間
目前US$5.97
52週區間
目前US$5.97
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 100萬 USD | 572.1萬 USD | 165.7萬 USD | 65.2萬 USD | 3001.7萬 USD |
| 銷貨成本 | 295.1萬 USD | 489.4萬 USD | 404.2萬 USD | 8219.9萬 USD | 138萬 USD |
| 毛利 | −195.1萬 USD | 82.7萬 USD | −238.5萬 USD | −8154.7萬 USD | 2863.7萬 USD |
| 研究與開發 | 3527.3萬 USD | 6721.1萬 USD | 7431萬 USD | 8289.9萬 USD | 5656.3萬 USD |
| 銷售、一般及管理費用 | 1723.5萬 USD | 1907.7萬 USD | 1930.4萬 USD | 1968.2萬 USD | 1872.3萬 USD |
| 營業費用 | 4955.7萬 USD | 8139.4萬 USD | 8957.2萬 USD | 2178.2萬 USD | 7390.6萬 USD |
| 利息收入 | 270.3萬 USD | 517.4萬 USD | 466.9萬 USD | 159.2萬 USD | 62.5萬 USD |
| 折舊和攤銷 | 368.8萬 USD | 382.9萬 USD | 404.2萬 USD | 307.3萬 USD | 138萬 USD |
| 營業利益 | −5150.8萬 USD | −8056.7萬 USD | −9195.7萬 USD | −1.03億 USD | −4526.9萬 USD |
| 淨利 | −4880.9萬 USD | −7541萬 USD | −8729.8萬 USD | −1.02億 USD | −4497.4萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$14.67
上漲空間 145.73%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1659萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1212.1萬0.02%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1051.14萬0.11%98.74億 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF544.61萬0.01%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO372.22萬0.03%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO246.98萬0.01%180億 USD0.06%US$112.66+0.50%
Fidelity Enhanced Small Cap ETFFESM221.46萬0.03%64.1億 USD0.28%US$45.46+0.46%
Vanguard Health Care ETFVHT153.38萬0.01%220億 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
